Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844786 | 0.95 | NCF1 (0.34) | KDM4ECHRM3TP53ALDH1A1HTT | |
| SCHEMBL2741654 | 0.95 | NCF1 (0.34) | KDM4ECHRM3TP53ALDH1A1HTT | |
| SCHEMBL19242182 | 0.95 | NCF1 (0.34) | KDM4ECHRM3TP53ALDH1A1HTT | |
| SCHEMBL26057811 | 0.95 | KDM4E (0.38) | KDM4ECHRM3TP53ALDH1A1LMNA | |
| SCHEMBL463378 | 0.85 | CACNA2D1 (0.35) | HTT | |
| SCHEMBL462404 | 0.85 | CACNA2D1 (0.35) | HTT | |
| SCHEMBL15837593 | 0.85 | CACNA2D1 (0.35) | HTT | |
| SCHEMBL105239 | 0.83 | NCF1 (0.40) | NCF1OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL13890375 | 0.78 | KAT2B (0.35) | KDM4ECHRM3TP53 | |
| SCHEMBL17173932 | 0.78 | KAT2B (0.35) | KDM4ECHRM3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515448-B1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-11008572-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008572-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885CHRM3 4629/4885TP53 1932/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | KDM4E 718/4885CHRM3 236/4885TP53 417/4885 |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | PGK1, PHKG1, NEK1 | KDM4E 1246/4885CHRM3 4438/4885TP53 531/4885 |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885CHRM3 4629/4885TP53 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.